CA2549672C - Antineutrophilia agent using 3(2h)-pyridazinone compounds - Google Patents

Antineutrophilia agent using 3(2h)-pyridazinone compounds Download PDF

Info

Publication number
CA2549672C
CA2549672C CA2549672A CA2549672A CA2549672C CA 2549672 C CA2549672 C CA 2549672C CA 2549672 A CA2549672 A CA 2549672A CA 2549672 A CA2549672 A CA 2549672A CA 2549672 C CA2549672 C CA 2549672C
Authority
CA
Canada
Prior art keywords
antineutrophilia
hydrogen atom
pyridazinone
agent
halogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2549672A
Other languages
English (en)
French (fr)
Other versions
CA2549672A1 (en
Inventor
Takehisa Iwama
Nobutomo Tsuruzoe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp, Taisho Pharmaceutical Co Ltd filed Critical Nissan Chemical Corp
Publication of CA2549672A1 publication Critical patent/CA2549672A1/en
Application granted granted Critical
Publication of CA2549672C publication Critical patent/CA2549672C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA2549672A 2003-12-26 2004-12-22 Antineutrophilia agent using 3(2h)-pyridazinone compounds Expired - Fee Related CA2549672C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003-433747 2003-12-26
JP2003433747 2003-12-26
PCT/JP2004/019199 WO2005063250A1 (ja) 2003-12-26 2004-12-22 好中球増多抑制剤

Publications (2)

Publication Number Publication Date
CA2549672A1 CA2549672A1 (en) 2005-07-14
CA2549672C true CA2549672C (en) 2010-06-22

Family

ID=34736527

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2549672A Expired - Fee Related CA2549672C (en) 2003-12-26 2004-12-22 Antineutrophilia agent using 3(2h)-pyridazinone compounds

Country Status (12)

Country Link
US (2) US20070117806A1 (enExample)
EP (1) EP1698339A4 (enExample)
JP (1) JP4688681B2 (enExample)
KR (2) KR101293350B1 (enExample)
CN (1) CN1897952B (enExample)
AU (1) AU2004308806B9 (enExample)
BR (1) BRPI0417200A (enExample)
CA (1) CA2549672C (enExample)
IL (1) IL176473A (enExample)
RU (1) RU2356555C2 (enExample)
TW (1) TW200522962A (enExample)
WO (1) WO2005063250A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101538245B (zh) * 2008-03-18 2011-02-16 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和制备药物的用途
CN102133217B (zh) * 2010-01-27 2013-07-24 中国科学院上海药物研究所 一类以n为桥键的哒嗪酮类化合物在制备抗肿瘤的药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2149761T3 (es) * 1990-04-25 2000-11-16 Nissan Chemical Ind Ltd Derivado de piridazinona.
IL112695A (en) * 1994-02-22 1999-04-11 Green Cross Corp Pharmaceutical compositions containing pyridazinone derivatives
DK1025847T3 (da) * 1997-08-28 2006-02-13 Nissan Chemical Ind Ltd Neovaskulariseringspromotorer og neovaskulariseringsforstarkere
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
RU2229297C2 (ru) * 1998-09-01 2004-05-27 Ниссан Кемикал Индастриз, Лтд. Терапевтический агент для лечения стеноза позвоночного канала
GB9824160D0 (en) * 1998-11-04 1998-12-30 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
CA2353956C (en) * 1998-12-07 2008-10-28 Nissan Chemical Industries, Ltd. Remedial agent for erectile dysfunction
ES2215631T3 (es) * 1999-03-23 2004-10-16 Hollis-Eden Pharmaceuticals Inc. Hemihidrato de 16alfa-bromoepiandrosterona.
JP2001131088A (ja) * 1999-11-02 2001-05-15 Kyurin:Kk シンドロームｘ症候群治療剤

Also Published As

Publication number Publication date
TW200522962A (en) 2005-07-16
TWI341729B (enExample) 2011-05-11
IL176473A (en) 2013-06-27
IL176473A0 (en) 2006-10-05
KR20060125816A (ko) 2006-12-06
RU2356555C2 (ru) 2009-05-27
US20070117806A1 (en) 2007-05-24
KR20100019542A (ko) 2010-02-18
KR101293350B1 (ko) 2013-08-05
AU2004308806B2 (en) 2009-10-29
RU2006127040A (ru) 2008-02-10
EP1698339A1 (en) 2006-09-06
WO2005063250A1 (ja) 2005-07-14
AU2004308806A1 (en) 2005-07-14
CN1897952A (zh) 2007-01-17
JPWO2005063250A1 (ja) 2007-07-19
BRPI0417200A (pt) 2007-02-06
JP4688681B2 (ja) 2011-05-25
US20080306080A1 (en) 2008-12-11
CN1897952B (zh) 2010-12-08
AU2004308806B9 (en) 2010-01-28
CA2549672A1 (en) 2005-07-14
HK1098378A1 (en) 2007-07-20
EP1698339A4 (en) 2009-06-17

Similar Documents

Publication Publication Date Title
TWI664967B (zh) 新穎化合物（一）
JP5602748B2 (ja) トリアゾール含有マクロライドを用いた生体防御
CZ286816B6 (en) Benzimidazole derivatives, and pharmaceutical preparations in which they are comprised and their use for preparing medicaments
EP3458448B1 (en) Fasn inhibitors for use in treating non-alcoholic steatohepatitis
US20080306080A1 (en) Neutrophilia inhibitor
US20090155187A1 (en) Drug for inhibiting vascular intimal hyperplasia
EP4525858A1 (en) Methods of treatment for cystic fibrosis
MXPA06007434A (en) Neutrophilia inhibitor
HK1098378B (en) Neutrophilia inhibitor
JP2014208611A (ja) Ｉｌ−２産生抑制
US20050222234A1 (en) Mucin production inhibitor
EP1676575A2 (en) Mucin production inhibitor
CN117562915A (zh) 一种腺苷衍生物在制备预防、缓解或治疗纤维化疾病的药物中的应用
MXPA06009004A (en) Drug for inhibiting vascular intimal hyperplasia
CA2520577A1 (en) Pharmaceutical composition
JPWO1994027607A1 (ja) 抗ウイルス剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181224